The pharma industry is at a turning point. One future leads to bottlenecks from tighter cost controls, regulatory gridlock and declining access and outcomes. The other future could be a new era of breakthroughs—one where data, technology and AI fuel a transformation in personalized healthcare.
At Reuters EU Pharma 2025, Bill Coyle, chair of ZS’s shareholder council and former global head of biopharma, shared his view on where the industry will go next.
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
